文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

基于人群的多国队列研究中幽门螺杆菌根除治疗后食管腺癌的风险

Risk of Esophageal Adenocarcinoma After Helicobacter pylori Eradication Treatment in a Population-Based Multinational Cohort Study.
PubMed 文献 · Gastroenterology · 2024-03-19

该多国队列纳入1995—2018年5个北欧国家接受幽门螺杆菌根除治疗的661987名成人,随访至2019年。根除治疗后食管腺癌总体标准化发病比未升高(SIR=0.89;95%CI,0.82-0.97),且随治疗后时间延长而下降,11—24年时为0.73(95%CI,0.61-0.86)。作者认为从癌症角度看根除治疗是安全的。

要点

  • 根除治疗后食管腺癌总体SIR为0.89(95%CI,0.82-0.97),未升高。
  • 根除治疗后11—24年食管腺癌SIR为0.73(95%CI,0.61-0.86)。
  • 食管鳞状细胞癌SIR为0.99(95%CI,0.89-1.11),无关联。

核心结论

  • 根除幽门螺杆菌后未见食管腺癌风险升高,作者认为从癌症角度看根除治疗是安全的。

研究设计与样本

  • 基于人群的多国队列研究「北欧幽门螺杆菌根除项目(NordHePEP)」,纳入1995—2018年5个北欧国家(丹麦、芬兰、冰岛、挪威、瑞典)接受幽门螺杆菌根除治疗的≥18岁成人,随访至2019年,数据来自国家登记库。

主要发现

  • 661987名参与者根除治疗后贡献5495552人年(中位随访7.8年;范围1—24年),发生550例食管腺癌。
  • 食管腺癌总体SIR为0.89(95%CI,0.82-0.97),未升高。
  • 根除治疗后食管腺癌SIR随时间未升高而是下降,11—24年时为0.73(95%CI,0.61-0.86)。
  • 按教育、合并症、胃食管反流及某些药物分层分析未见重大差异。
  • 作为对照计算的食管鳞状细胞癌总体SIR为0.99(95%CI,0.89-1.11),无关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Helicobacter pylori infection is associated with a decreased risk of esophageal adenocarcinoma, and the decreasing prevalence of such infection might contribute to the increasing incidence of this tumor. We examined the hypothesis that eradication treatment of H pylori increases the risk of esophageal adenocarcinoma. METHODS: This population-based multinational cohort, entitled "Nordic Helicobacter Pylori Eradication Project (NordHePEP)," included all adults (≥18 years) receiving H pylori eradication treatment from 1995-2018 in any of the 5 Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden) with follow-up throughout 2019. Data came from national registers. We calculated standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) by dividing the cancer incidence in the exposed cohort by that of the entire Nordic background populations of the corresponding age, sex, calendar period, and country. Analyses were stratified by factors associated with esophageal adenocarcinoma (ie, education, comorbidity, gastroesophageal reflux, and certain medications). RESULTS: Among 661,987 participants who contributed 5,495,552 person-years after eradication treatment (median follow-up, 7.8 years; range, 1-24 years), 550 cases of esophageal adenocarcinoma developed. The overall SIR of esophageal adenocarcinoma was not increased (SIR = 0.89; 95% CI, 0.82-0.97). The SIR did not increase over time after eradication treatment, but rather decreased and was 0.73 (95% CI, 0.61-0.86) at 11-24 years after treatment. There were no major differences in the stratified analyses. The overall SIR of esophageal squamous cell carcinoma, calculated for comparison, showed no association (SIR = 0.99; 95% CI, 0.89-1.11). CONCLUSIONS: This absence on an increased risk of esophageal adenocarcinoma after eradication treatment of H pylori suggests eradication is safe from a cancer perspective.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Wiklund AK, Santoni G, Yan J, et al. Risk of Esophageal Adenocarcinoma After Helicobacter pylori Eradication Treatment in a Population-Based Multinational Cohort Study. Gastroenterology. 2024. PMID: 38513743. doi:10.1053/j.gastro.2024.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。